MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
NEW YORK, Nov. 17, 2016 -- Safirstein Metcalf LLP announces that a class action has been filed in the United States District Court for the Middle District of North Carolina on behalf of purchasers of Cempra Inc. ("Cempra") (NASDAQ:CEMP) securities between May 1, 2016 and November 1, 2016 (the "Class Period").
If you purchased Cempra securities during the class period, and would like more information about getting involved in the Cempra Securities Class Action, please contact Sheila Feerick at 1-800-221-0015, or email [email protected]
If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
The Complaint alleges that throughout the Class Period, defendants issued false and misleading statements to investors and/or failed to disclose that: (1) solithromycin posed significant safety risks for hepatotoxicity; and (2) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.
On November 2, 2016, the United States Food and Drug Administration (“FDA”) posted on its website a briefing document addressing solithromycin. The FDA reported that “[a] significant safety signal for hepatotoxicity was observed in the solithromycin development program,” and there was concern for “the high rate of infusion site-related reactions.” On this news, Cempra stock fell $11.35, or 60.86%, to close at $7.30 on November 2, 2016.
On November 4, 2016, Cempra issued a press release announcing that NASDAQ has halted trading of the Company’s common stock. Cempra also announced that the FDA Antimicrobial Drugs Advisory Committee (“AMDAC”) would meet that day to discuss the safety and efficacy of solithromycin to treat community-acquired bacterial pneumonia.
About Safirstein Metcalf LLP
Safirstein Metcalf LLP focuses it practice on shareholder rights. The law firm also practices in the areas of antitrust and consumer protection. All of the Firm’s legal endeavors are rooted in its core mission: provide investor and consumer protection.
Attorney advertising. Prior results do not guarantee a similar outcome.
Safirstein Metcalf LLP Peter Safirstein, Esq. 1250 Broadway 27th Floor New York, NY 10001 1-800-221-0015 [email protected]
